Two years' experience with Dialock and CLS (a new antimicrobial lock solution).
Sodemann
K
K
Dialysis Center, Lahr-Ettenheim, Germany. sodemann@compuserve.com
Polaschegg
H D
HD
Feldmer
B
B
D000328:Adult; D000890:Anti-Infective Agents; D000925:Anticoagulants; D002405:Catheterization, Central Venous / Q000009:adverse effects / Q000295:instrumentation*; D002408:Catheters, Indwelling / Q000009:adverse effects; D019343:Citric Acid; D004867:Equipment Design; D005268:Femoral Vein; D006325:Heart Atria; D006801:Humans; D015994:Incidence; D017053:Infection Control / Q000295:instrumentation*; D007601:Jugular Veins; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D010865:Pilot Projects; D006435:Renal Dialysis / Q000295:instrumentation*; D012189:Retrospective Studies; D018570:Risk Assessment; D012449:Safety; D018805:Sepsis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D012996:Solutions; D013350:Subclavian Vein; D013654:Taurine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D013829:Thiadiazines / Q000009:adverse effects / Q000493:pharmacokinetics
D000890:Anti-Infective Agents; D000925:Anticoagulants; D012996:Solutions; D013829:Thiadiazines; D013654:Taurine; D019343:Citric Acid; C012566:taurolidine